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Immunotherapy of cancer utilizes dendritic cells (DCs) for antigen presentation and the
induction of tumor-specific immune responses. However, the therapeutic induction of
anti-tumor immunity is limited by tumor escape mechanisms. In this study, immortal-
ized dendritic D2SC/1 cells were transduced with a mutated version of the p53 tumor
suppressor gene, p53M234I, or p53C132F/E168G, which are overexpressed in MethA
fibrosarcoma tumor cells. In addition, D2SC/1 cells were fused with MethA tumor cells
to generate a vaccine that potentially expresses a large repertoire of tumor-antigens. Cellu-
lar vaccines were transplanted onto Balb/c mice and MethA tumor growth and anti-tumor
immune responses were examined in vaccinated animals. D2SC/1–p53M234I and D2SC/1–
p53C132F/E168G cells induced strong therapeutic and protective MethA tumor immunity
upon transplantation in Balb/c mice. However, in a fraction of immunized mice MethA
tumor growth resumed after an extended latency period. Analysis of these tumors indi-
cated loss of p53 expression. Mice, pre-treated with fusion hybrids generated from D2SC/1
and MethA tumor cells, suppressed MethA tumor growth and averted adaptive immune
escape. Polyclonal B-cell responses directed against various MethA tumor proteins could
be detected in the sera of D2SC/1–MethA inoculated mice. Athymic nude mice and Balb/c
mice depleted of CD4+ or CD8+ T-cells were not protected against MethA tumor cell
growth after immunization with D2SC/1–MethA hybrids. Our results highlight a potential
drawback of cancer immunotherapy by demonstrating that the induction of a specific anti-
tumor response favors the acquisition of tumor phenotypes promoting immune evasion.
In contrast, the application of DC/tumor cell fusion hybrids prevents adaptive immune
escape by a T-cell dependent mechanism and provides a simple strategy for personalized
anti-cancer treatment without the need of selectively priming the host immune system.
Keywords: immune surveillance of cancer, tumor-specific antigen expressing dendritic cells, adaptive immune
escape, dendritic cell–tumor cell fusion, CD8+ T-cell mediated tumor suppression
INTRODUCTION
Progress in understanding the molecular basis of cancer etiol-
ogy and insights into immunological defense mechanisms have
led to promising new treatment options in the past decade (1–
5). In addition to conventional chemotherapeutic agents, targeted
compounds and immunotherapy have been added to the clini-
cians’ armamentarium. The enhancement of the immune system
has been validated as a promising therapeutic strategy to elicit
tumor-specific responses, to induce durable tumor regression, and
to improve survival intervals of patients (6). However, objective
Abbreviations: CD, clusters of differentiation; CTL, cytolytic T-lymphocytes; DC,
dendritic cells; FITC, fluorescein isothiocyanate; GM-CSF, granulocyte macrophage
colony-stimulating factor; HRP, horseradish-peroxidase; IL, interleukin; i.v., intra-
venous; MHC, major histocompatibility complex; mp53, mutant p53; s.c., subcuta-
neous; TA, tumor antigen.
clinical responses in patients subjected to immunotherapy are
still insufficient. Benefits have only been observed in a fraction
of patients and tumor-specific immune responses often did not
correlate with tumor rejection, stabilization of disease, or overall
survival (7). Considerable efforts are necessary to further improve
immunotherapy of cancer and to gain insight into the complex
interplay of tumor cells with the immune system (8, 9).
Tumor cells are poor antigen presenting cells. Therefore, the
induction of protective immunity depends upon efficient tumor
antigen (TA) presentation by professional antigen presenting cells
(10). Activated DCs display surface antigens via major histocom-
patibility complexes (MHC) class I and class II in combination
with co-stimulatory molecules, e.g., B7-1 and B7-2, and are able to
interact with naïve CD4+ and CD8+ T-cells to trigger T-cell prolif-
eration and differentiation (11, 12). Differentiated cytolytic CD8+
T-lymphocytes (CTLs) are the most important effector cells for
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anti-tumor immune responses (13). DCs are also able to interact
with B-cells and thus stimulate specific antibody production (13).
DCs have successfully been used as cancer vaccines by presentation
of TAs (14).
However, therapeutic DC application is restricted by the lim-
ited number of known proteins, specifically expressed in tumor
tissue and able to elicit an appropriate MHC-dependent immune
response. For this reason, DCs have been pulsed with whole tumor
lysates or have been fused with tumor cells to express and present
multiple and unidentified TAs and to increase the frequency of
responding immune effector cells (15, 16). The presentation of
TAs in the context of abundant co-stimulation probably also
avoids the induction of tolerance and promotes the polyclonal
activation of helper T-cells and CTL responses (17). Furthermore,
DCs are composed of multiple subsets, some of them essential
for establishing tolerance through T-cell deletion and activation
of regulatory T-cells (11). In contrast, CD8α+ DCs and DCs
differentiated in medium with granulocyte macrophage colony-
stimulating factor (GM-CSF) and IL-15 seem most suitable to
induce antigen-specific CTLs (18, 19). The deployment of estab-
lished DCs for analysis or comparison of antigen induced tumor
responses could possibly circumvent potential problems, stem-
ming from the logistics of primary cell culture, cytokine treat-
ment, and the distinguishable properties of DC subsets. A cell
line, D2SC/1 cells, has been established from mouse spleen, which
exhibits dendritic cell (DC) properties and which was shown to be
fully competent in bacterial or viral antigen presentation and the
induction of primary T-cell responses (20–22).
The established fibrosarcoma tumor cell line MethA overex-
presses two mutated versions of the p53 tumor suppressor gene,
p53M234I, and p53C132F/E168G. Mutant p53 (Mp53) might
contribute to the genesis of neo-antigens that provide epitopes
exclusively expressed on the surface of tumor cells. Such T-cell
determinants seem most suited for immune therapeutical inter-
ventions (23). In addition, p53 is expressed at nearly undetectable
levels in normal tissues; however, mutations in p53 usually result
in a prolonged half life and marked accumulation of mp53 has
been observed in approximately 50% of human tumors. Mutated
or overexpressed p53 are immunogenic. p53-derived epitopes in
MHC-class I and MHC-class II complexes, MHC-class I and class
II restricted p53-specific CTLs or CD4+ helper T-cells, and p53-
specific circulating antibodies have been demonstrated (24–26).
Experimental mouse models have used overexpression of p53
to induce immunogenicity and to achieve tumor rejection (27,
28). p53-specific immune responses have also been initiated by
vaccination of cancer patients (29, 30).
The interaction of tumor cells with the immune system causes
reciprocal evolutionary pressure. Tumors facilitate their own sur-
vival by formation of a cytokine microenvironment promoting
angiogenesis and cell cycle progression and antagonize immune
functions through pro-apoptotic signaling, prevention of efficient
antigen processing and presentation, or the induction of immuno-
suppressive regulatory T-cells (14, 31). Another escape mechanism
of cancer cells is based on adaptive resistance. Targeted treatment
may lead to the reprograming of signaling networks and changes
in gene expression patterns that result in resistance to particu-
lar drugs or loss of sensitivity against immune cells (32–34). This
escape mechanism may potentially be blocked by the use of vac-
cines, which target all or most available antigens of a particular
tumor cell. Vaccines which can compensate for the loss of a single
TA may have a greater therapeutic potential (35).
We have compared the effectiveness of a DC vaccine based
on the expression of a single TA, mp53, in D2SC/1 cells and a
vaccine based on the presentation of a large number of poten-
tial antigens achieved through the fusion of MethA tumor cells
with D2SC/1 DCs. Our experiments show that D2SC/1 cells can
become potent inducers of anti-tumor immunity upon transfer of
a mutated version of the p53 gene or the fusion with entire MethA
tumor cells. An immune escape, seen in a fraction of D2SC/1–
mp53 vaccinated mice, does not occur in mice vaccinated with
the D2SC/1–MethA fusion cells. Fusion hybrids were more potent
in stimulating anti-tumor immune responses because one single
application was sufficient to induce immediate, comprehensive,
and robust in vivo immune protection. Furthermore, TA-loaded
D2SC/1 cells represent an attractive option to evaluate the immune
stimulatory potential of diverse TAs.
MATERIALS AND METHODS
MICE AND CELL LINES
Female Balb/c (H-2d) mice were used at 6–8 weeks of age and pur-
chased from Charles River (Sulzfeld, Germany). Female C57BL/6
(H-2b) and Balb/c athymic nude mice (H-2d) were obtained from
Harlan Winkelmann (Borchen, Germany). All animal experiments
were approved by the Regional Council of Freiburg and carried
out in accordance with official regulations for care and use of
laboratory animals.
MethA (H-2d) is a 3-methylcholanthrene induced fibrosar-
coma, which arose in a Balb/c mouse (36). MethA tumor cells
were cultured in RPMI 1640 medium, supplemented with 10%
fetal calf serum. The HT1080-based packaging cell line FLY-AF-
13 and the LacZ producer clone FLYA4lacZ3 were obtained from
B. Schnierle, Langen, Germany (37). D2SC/1 (H-2d) are immor-
talized dendritic mouse cells isolated from spleen and were pro-
vided by U. Altenschmidt, Freiburg, Germany (21). FLY-AF-13,
FLYA4lacZ3, and D2SC/1 cells were grown in Dulbecco’s modified
Eagle medium and 10% fetal calf serum.
GENE TRANSFER BY RETROVIRAL TRANSDUCTION
The open reading frames of the two mp53 alleles present in
MethA tumor cells were cloned by RT-PCR, using the primer pair
TCCGAAGCTTGGATGACTGC and GCAGAGGAATTCAGTCT-
GAGTCA. The missense point mutations C132F, E168G, and
M234I present in the p53 alleles were verified by sequence analysis.
p53M234I and p53C132F/E168G were cloned into the retrovi-
ral transduction vector pBABEpuro (Addgene, Cambridge, MA,
USA). Stable amphotropic packaging cell lines were generated by
calcium phosphate transfection of the mp53 vector constructs into
the HT1080-based packaging cell line FLY-AF-13 and puromycin
selection (5µg/ml puromycin; Life Technologies, Darmstadt, Ger-
many). Virus was obtained from producer cell lines at 40–60%
confluence by replacing growth medium with 100µl/cm2 RPMI
1640 medium, 10% FCS, and harvesting the conditioned medium
15 h later. Retroviral transduction was performed by filtering pro-
ducer cell culture medium through a Pro-X™ 0.22µM syringe
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filter (Roth, Karlsruhe, Germany) and adding it undiluted to 40%
confluent, logarithmically growing D2SC/1 cells. Transduction
was repeated at intervals of 15 h.
STAINING OF LacZ TRANSDUCED CELLS
Cells were fixed in 0.05% glutaraldehyde in phosphate buffered
saline for 5 min at room temperature and stained in 137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 2 mM MgCl2,
16 mM K3Fe(CN)6, and 16 mM K4Fe(CN)6 containing 1 mg/ml
X-gal substrate (Sigma-Aldrich, St. Louis, MO, USA) for 6–48 h at
37°C. LacZ positive cells appeared blue under the microscope.
GENERATION OF CELL FUSION HYBRIDS
The vector pBABEhygro (Addgene) was introduced into MethA
tumor cells by calcium phosphate precipitation to obtain
hygromycin B resistant clones. D2SC/1 cells were similarly trans-
fected with pBABEpuro. Transfected cells were cultured in growth
medium containing 5µg/ml puromycin or 100µg/ml hygromycin
(Life Technologies). To obtain fusion hybrid cells, 107 hygromycin
resistant MethA tumor cells were mixed with 5× 107 puromycin
resistant D2SC/1 cells and briefly centrifuged. Cellular pellets
were gently resuspended in 1 ml PEG 4000 (Merck, Darmstadt,
Germany) containing 0.5 ml RPMI 1640 medium and incubated
at 37°C for 90 s. Subsequently, 15 ml RPMI 1640 medium was
added drop wise to the cells, then 20 ml RPMI 1640 medium with
10% fetal calf serum. After 5 min the cell suspension was cen-
trifuged and cells were plated in RPMI 1640 medium and 10%
fetal calf serum. After 24 h the fused cell hybrids were selected in
the presence of 100µg/ml hygromycin and 5µg/ml puromycin.
When colonies were developed, individual hybrid cell clones were
isolated using cloning cylinders (Sigma-Aldrich) and 50µl of
trypsin-EDTA.
IMMUNIZATION OF MICE
pBABE-LacZ, pBABE-p53M234I, or pBABE-p53C132F/E168G
transduced D2SC/1 cells were irradiated with 50 gray and injected
either intravenously (i.v.) into the tail vein or subcutaneously (s.c.)
in the right flank of female Balb/c mice. 5× 106 mp53-transduced
D2SC/1 cells were used for each injection. Injections were repeated
five times in intervals of 10 days. Sixty days after onset of immu-
nization mice were inoculated with 5× 106 non-irradiated MethA
tumor cells by s.c. injection into the left flank.
Alternatively, 24 different cell hybrid clones, obtained by fusion
of MethA tumor cells and D2SC/1 DCs were randomly chosen
for immunization of female Balb/c mice or athymic Balb/c nude
mice. 5× 106 non-irradiated hybrid cells were injected s.c. into
the right flank of each mouse. After 4 weeks the immunized mice
were inoculated with 5× 106 parental MethA tumor cells in the
opposite flank. Tumor growth was monitored by palpation and
calculated with vernier calipers based on the formula: tumor vol-
ume= (shortest diameter)2× longest diameter/2. Tumor bearing
mice were sacrificed on day 30 (s.c. tumor cell transplantation)
or when animals displayed significant tumor necrosis (s.c. tumor
cell transplantation), dyspnea, ataxia, weight loss, or lethargy (i.v.
tumor cell application).
FLOW CYTOMETRY
Cell surface proteins were analyzed by a FACScan flow cytometer
and the Lysis II software (BD Biosciences, Heidelberg, Germany).
Briefly, 106 cells were incubated with the specific primary antibody
detecting B7-1 (clone 16-10A1),B7-2 (clone GL-1),H-2K[d] (SF1-
1.1), H-2D[d] (clone 34-2-12), or I-A[d] (AMS-32.1) in 20µl of
phosphate buffered saline. After 45 min cells were washed and
incubated with a fluorescein isothiocyanate (FITC) conjugated
secondary antibody for 30 min. Antibody concentrations were
used as indicated by the manufacturer (BD Biosciences). Free anti-
bodies were removed by washing and samples were analyzed by
flow cytometry in 500µl of phosphate buffered saline.
For detection of intracellular p53, cells were suspended in 1 ml
RPMI 1640 medium containing 50% fetal calf serum and fixed
for 30 min on ice by drop wise addition of 3 ml 100% ethanol at
−20°C. Then cells were washed with 3× 10 ml phosphate buffered
saline before an anti-p53 antibody (PAb 421, Millipore, Schwal-
bach, Germany) and a FITC conjugated secondary antibody (BD
Biosciences) were added according to the recommendations of
the manufacturer. Flow cytometry was performed in a volume
of 500µl phosphate buffered saline, after removing unbound
antibodies by washing.
IMMUNOBLOTTING
MethA tumor cells were lysed in 150 mM NaCl, 10 mM Tris-
HCl/pH 7.5, and 0.5% Triton X-100. Cell debris was removed
by centrifugation at 13,000× g for 5 min at 4°C, and protein con-
centrations of the cleared cellular lysates were determined by the
bicinchoninic acid assay (Pierce, Rockford, IL, USA). The samples
were mixed 1:1 with sample buffer (100 mM Tris-HCl/pH 6.8,
20% glycerol (v/v), 4% SDS, 200 mM dithiothreitol, and 0.02%
bromphenol blue), boiled for 5 min, and 75µg total protein of
the cell lysate per centimeter was separated on a preparative
10% SDS-PAGE gel. Proteins were transferred to an Immobilon-
P membrane (Millipore) that was cut to vertical stripes before
non-specific binding sites were blocked for 1 h in blocking buffer
(50 mM Tris-HCl/pH 7.6, 150 mM NaCl, 0.05% Tween 20, and
2.5% non-fat dry skim milk). Individual stripes were incubated
for 1 h with mouse sera (1:400 in blocking buffer) and subse-
quently with a secondary horseradish-peroxidase (HRP)-labeled
sheep anti-mouse IgG (1:5000; GE Healthcare, Little Chalfont,
UK) for 40 min. MethA antibody complexes were visualized by
the Amersham ECL™ Advance Western Blotting Detection Kit
(GE Healthcare).
To detect endogenous p53, 75µg of MethA tumor cell lysate
were resolved by 10% SDS-PAGE, transferred to an Immobilon-
P membrane, blotted with 1µg/ml anti-p53 PAb 421 (Millipore)
or β-actin antibody (1:1000, Cell Signaling Technology, Danvers,
MA, USA) and specific bands were visualized by HRP-conjugated
anti-mouse or anti-rabbit IgG and enhanced chemiluminescence
reagents (GE Healthcare).
To detect p53-specific antibodies in mouse sera, the full
open reading frame of mp53C132F/E168G or mp53M234I was
cloned into the bacterial expression vector pRSET-C (Life Tech-
nologies) and after transformation of E. coli BL21-(DE3)LysS
recombinant mp53 was purified by nickel-nitrilotriacetate column
chromatography as previously described (38). Purified protein
(100 ng/cm) was separated on preparative 10% SDS-PAGE gels
and immobilized on Immobilon-P stripes that were individu-
ally blotted with mouse sera at a dilution of 1:400 or 1µg/ml
anti-p53 PAb 421 antibody. Mp53 antibody complexes were
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visualized by HRP-conjugated anti-mouse IgG and enhanced
chemiluminescence reagents.
ISOLATION OF MOUSE T-CELLS AND DENDRITIC CELLS
T-lymphocytes from spleens of mice were isolated as described
(39). Mice were sacrificed and the spleen was gently dissociated
through a 200µm mesh screen into a single cell suspension. Red
blood cells were removed by lysis in 150 mM NH4Cl/pH 7.2, 1 M
KHCO3, and 100 mM EDTA for 5 min. To enrich T-lymphocytes,
spleen cell suspensions were passed through scrubbed nylon fiber
wool columns that were pre-equilibrated with phosphate buffered
saline and 10% fetal calf serum. Cells were allowed to adhere by
incubating the loaded columns for 45 min at 37°C in a humidi-
fied incubator. Non-adherent cells were eluted in growth medium
(Dulbecco’s modified Eagles medium, 10% fetal calf serum,
50µM β-mercaptoethanol, 1 mM Hepes/pH 7.4, 100µg/ml strep-
tomycin, and 100 U/ml penicillin) and a fraction was analyzed by
flow cytometry using an anti-CD3 phycoerythrin conjugated anti-
body according to the manufacturers description (clone 17A2, BD
Biosciences). Eluted, non-attached cells were routinely 80–90%
CD3+ T-cells.
Dendritic cells from spleen were enriched by positive selection
using magnetic beads coupled to anti-mouse CD11c antibod-
ies (clone N418, Miltenyi Biotec, Bergisch Gladbach, Germany).
Briefly, 108 spleen cells were suspended in 400µl phosphate
buffered saline, 10% fetal calf serum, and 2 mM EDTA and were
co-incubated with 100µl CD11c microbeads for 15 min at 4°C.
Magnetically labeled cells were passed through a pre-equilibrated
LS+ positive selection column, placed within a magnetic field of a
MACS separator (Miltenyi Biotec). Unlabeled cells were removed
by washing the column with 9 ml phosphate buffered saline, sup-
plemented with 10% fetal calf serum and 2 mM EDTA. The
column was removed from the magnetic field and CD11c posi-
tive cells were eluted as a positive selected cell fraction. DCs were
maintained in growth medium containing Dulbecco’s modified
Eagel’s medium, 10% fetal calf serum, 50 µM β-mercaptoethanol,
1 mM Hepes/pH 7.4, 100µg/ml streptomycin, 100 U/ml penicillin,
5 ng/ml recombinant mouse IL-4 (Genzyme, Rüsselsheim, Ger-
many), and 20 ng/ml recombinant mouse GM-CSF (Genzyme).
Washed, adherent cells consisted of 90–98% DCs. Alternatively,
DCs were obtained from bone-marrow by flushing the femurs of
Balb/c mice as described previously (40). Bone-marrow derived
cell suspensions were pre-cultured in DC growth medium for
10 days before differentiated cells were enriched by using CD11c
microbeads and a MACS separator (Miltenyi Biotec).
T-CELL PROLIFERATION ASSAY
T-cells were plated at 1.28× 106 cells per well of a 96 well microtiter
plate or titrated 1:4 in triplicates. Proliferation of T-lymphocyte
effector cells was induced by 2× 104 irradiated D2SC/1 cells, bone-
marrow derived CD11c+ DCs, spleen derived CD11c+ DCs, or
MethA-D2SC/1 fusion hybrid clones. Cells were co-cultured in
200µl Dulbecco’s modified Eagle’s medium, 10% fetal calf serum,
100 U/ml penicillin, 100µg/ml streptomycin, 10 mM Hepes/pH
7.4, 50µM β-mercaptoethanol, and 0 4 ng/ml IL-2 (R&D Systems,
Wiesbaden, Germany) for 72 h. One microcurie of [3H]thymidine
(GE Healthcare) was added for the last 15 h. The labeled cells
were harvested onto cellulose filters (Dunn Labortechnik GmbH,
Asbach, Germany) and quenched (Ready Safe™, Liquid Scintilla-
tion Cocktail; Beckman Coulter, Krefeld, Germany). The amount
of [3H]thymidine incorporation was determined by a liquid scin-
tillation β-counter (LS 6500 Multi-Purpose Scintillation Counter;
Beckman Coulter).
IN VIVO DEPLETION OF CD4+ OR CD8+ T-CELLS
Every second day, mice were treated by intraperitoneal injection
with 100µg of mAb GK1.5 (anti-CD4) or mAb 2.43 (anti-CD8)
(Imgenex, San Diego, CA, USA) starting at 8 days before immu-
nization of Balb/c mice with 5× 106 MethA–D2SC/1 fusion hybrid
clones and challenge with 5× 106 parental MethA tumor cells.
Depletion of the respective population by 40–80% was confirmed
by flow cytometry using blood samples taken from the lateral tail
vein and staining of peripheral blood leukocytes with anti-CD4
(GK1.5) FITC or anti-CD8 (2.43) PE (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) before MethA tumor challenge. Mice with
≤60% depletion of CD4+ or CD8+ T-cells were excluded from
the experiment. MethA tumor growth was monitored by palpation
and the size of the tumor was determined by vernier microcalipers.
STATISTICAL ANALYSIS
Statistical differences between experimental groups were deter-
mined by performing one-way analysis of variance followed by
the Bonferroni’s post hoc test. Values are shown as ±standard
error of the means. Differences between groups were considered
to be significant at p< 0.05. Statistical analyzes were carried out
using the Prism software package (GraphPad Software Inc., La
Jolla, CA, USA).
RESULTS
GENERATION OF D2SC/1 DENDRITIC CELLS EXPRESSING THE MUTATED
p53 VARIANTS FOUND IN MethA FIBROSARCOMA CELLS
We analyzed the potential of immortalized dendritic D2SC/1
cells to induce an effective cellular immune response. D2SC/1
cells express the antigen presenting molecules MHC-class I and
MHC-class II and the co-stimulatory molecules B7-1 and B7-2
(Figure 1A) and are able to induce a strong allogeneic immune
response (Figure 1B). 2× 104 DCs/well caused a marked stimula-
tion of the proliferation of allogeneic naïve T-lymphocytes isolated
from C57/BL6 mice. D2SC/1 cells were nearly as efficient in stim-
ulating T-cell proliferation as primary DCs isolated from mouse
spleen or differentiated from bone-marrow cells (Figure 1B). The
capacity of D2SC/1 cells to stimulate T-cell activation is a necessary
prerequisite for its function as a cellular vaccine and its application
in experimental tumor therapy.
Gene transfer of TAs into DCs predetermines the presentation
of the transgene via the MHC-class I pathway and induction of
cytolytic antigen-specific target cells (41). Unfortunately, standard
transfection methods such as calcium phosphate precipitation,
lipofection, and electroporation did not allow the efficient trans-
fer of transgenes into D2SC/1 cells and primary DCs isolated from
mouse spleen or differentiated from bone-marrow (data on file).
For this reason, we established the conditions for retroviral gene
transfer and initially introduced the LacZ gene. D2SC/1 cells were
cultured in medium obtained as supernatants from the packaging
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FIGURE 1 | D2SC/1 (H-2d) immortalized dendritic mouse splenocytes
are potent stimulators of naïveT-cells. (A) Flow cytometric analysis of
D2SC/1 cells stained with anti-H-2K[d] (clone SF1-1.1), anti-H-2D[d] (clone
34-2-12), anti-I-A[d] (clone AMS-32.1), anti-B7-1 (clone 16-10A1), and
anti-B7-2 (clone GL-1) antibodies. Filled histograms represent control
staining without primary antibody (isotype control), open histograms the
indicated surface marker. (B) A [3H]thymidine proliferation assay to
determine T-cell activation. Allogeneic naïve T-cells from C57BL/6 mice
were used as effector cells and stimulated with 50 ng/ml phorbol
myristate acetate and 1 nM ionomycin ( ) or were co-cultured with
2×104 irradiated D2SC/1 cells ( ), primary DCs derived from spleen ( ),
or primary DCs from bone-marrow ( ). Effector cells were stimulated for
72 h at 37°C and pulsed for the last 15 h with 1µCi of [3H]thymidine.
Values represent triplicate samples after subtracting thymidine
incorporation in the absence of phorbol myristate acetate and ionomycin
or stimulator cells. Data are shown as ±standard error of the means of
three independent experiments using CD3+ T-lymphocytes and primary
DCs of different donors. Experimental groups were statistically evaluated
by performing one-way ANOVA followed by the Bonferroni’s post hoc
test. Statistical differences of alloresponsive D2SC/1 cells was only
observed versus phorbol myristate acetate and ionomycin treated cells
(**p<0.01; ***p<0.001).
cell line FLYA4lacZ3 and thus infected with LacZ encoding viruses
(37). Efficient gene transfer was observed and more than 70%
of the D2SC/1 cells displayed expression of the LacZ transgene
(Figure 2A).
We supplied D2SC/1 cells with mutant versions of the p53
gene present in MethA cells to construct an efficient cellu-
lar anti-tumor vaccine. Two mutant alleles of p53 (p53M234I
and p53C132F/E168G) were cloned from the methylcholan-
threne induced Balb/c sarcoma cell line MethA by RT-PCR and
introduced into the retroviral transduction vector pBABEpuro
(Figure 2B). The presence of the missense point mutations C132F,
E168G, or M234I in the vectors were confirmed by sequence
analysis (data on file). Stable amphotropic packaging cell lines
were generated by calcium phosphate transfection of p53M234I
or p53C132F/E168G vector constructs into the HT1080-based
packaging cell line FLY-AF-13 and subsequent puromycin selec-
tion. Conditioned medium from the stably transfected packag-
ing cell lines, containing the mp53 encoding retroviruses, was
added to logarithmically growing D2SC/1 cells. Multiple infec-
tions were performed to increase the transduction efficiency. After
three cycles of infection, transduction efficiency was found to be
between 75 and 98% as determined by flow cytometry (Figure 2C).
Two days post transduction cells were harvested, irradiated, and
used for the vaccination of Balb/c mice.
MUTANT p53 EXPRESSING D2SC/1 CELLS, SUPPLIED AS A CELLULAR
VACCINE, INDUCES IMMUNITY TO THE GROWTH OF TRANSPLANTED
MethA TUMOR CELLS
D2SC/1 cells are immortalized DCs. To prevent their outgrowth
after injection into mice, they were irradiated with 50 gray before
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FIGURE 2 | Retroviral transduction of D2SC/1 cells. (A) D2SC/1 cells were
cultured in the supernatant of the retroviral packaging cell line FLYA4lacZ3 for
24 h and LacZ transduced cells were visualized by X-gal staining. (B) The
mp53 retroviral transduction vectors are illustrated. Predicted K[d] restricted
peptide presentation is marked by a box. Amino acids at position 2, 3, 5, and
carboxyl termini function as anchors or auxiliary anchors within the MHC
pocket. (C) Flow cytometry of mp53-transduced D2SC/1. Stable amphotropic
packaging cell lines were generated by calcium phosphate transfection of
FLY-AF-13 cells with pBABEpuro–p53C132F/E168G or pBABEpuro–p53M234I
and puromycin selection before D2SC/1 cells were transduced three times
with 1.5–3×104 CFU/ml of budding virus for 15 h. Cells were fixed and stained
with 1µg/ml PAb 421 anti-p53 antibody. Filled histograms represent stained
cells transduced with the pBABEpuro control vector, open histograms
D2SC/1-p53C132F/E168G, or D2SC/1-p53M234I transduced cells.
their use as a cellular vaccine. The mice inoculated with the irra-
diated cells were monitored for up to 15 months and no growth of
the D2SC/1 cells was observed. The vaccination protocol is shown
in Figure 3. 5× 106 irradiated D2SC/1 cells were injected either
intravenously into the tail vein or subcutaneously into the right
flank of the animals. To boost the immune response, injections
were repeated five times in intervals of 10 days. Sixty days after the
first injection with D2SC/1 cells,mice were inoculated with 5× 106
MethA tumor cells by subcutaneous injection into the opposite,
left flank. Tumor growth was monitored by palpation and the size
of the tumors was determined by vernier microcalipers. The data
obtained 2 months after tumor cell implantation are shown in
Figure 3 and Table 1. Mice treated with irradiated D2SC/1 cells
that were infected with the control vector pBABEpuro harboring
the LacZ gene, developed no protective immunity and displayed
unrestricted MethA tumor growth. In contrast, mice inoculated
with irradiated D2SC/1 cells that were infected with the viral vec-
tor encoding mp53, were protected from MethA tumor growth in
27 out of 48 cases. Inhibition of tumor growth was observed when
both mp53 alleles were expressed in the D2SC/1 cells, indepen-
dent of the application route of the cellular vaccine. In the non-
protected, D2SC/1-mp53 vaccinated mice, the growth kinetics of
MethA tumors were identical to those observed in D2SC/1-LacZ
inoculated control mice (Figure S1 in Supplementary Material).
Two years later, mice were exposed a second time to MethA
tumor cells. All of the 23 vaccinated mice which had not devel-
oped tumors after the first round of tumor cell inoculation rejected
the transplanted tumor cells also in the second round. This indi-
cates the establishment of a long term immunological memory
(Figure 3).
After the first tumor cell inoculation, four D2SC/1–mp53 vac-
cinated mice that initially displayed no MethA tumor growth,
developed tumors with a delay of 2–3 months at the MethA
cell transplantation site. We hypothesized that the vaccination
of the mice with D2SC/1–mp53 cells caused a selective pres-
sure on the tumor and that tumor cells that grew out after
a latency period might have acquired a p53 negative pheno-
type preventing immunological recognition. The late appearing
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FIGURE 3 | Immunization protocol of Balb/c mice treated with
transduced D2SC/1 cells. Stable amphotropic packaging cell lines were
generated by calcium phosphate transfection of FLY-AF-13 cells with
pBABEpuro–p53C132F/E168G or pBABEpuro–p53M234I and puromycin
selection before D2SC/1 cells were transduced with 1.5–3×104 CFU/ml
of budding virus for three times and irradiated with 50 grays. Mice
received 5×106 transduced and irradiated D2SC/1 cells s.c. in the right
flank or i.v. in the tail vain every 10 days. Sixty days after onset of
immunization, recipient mice were inoculated with 5×106 MethA tumor
cells by subcutaneous injection into the left flank. MethA tumor
resistance of mice was accessed at day 120. The amount of tumor free
mice and the administered cellular vaccine are indicated within the
diagram. Tumor resistant mice were re-challenged with 5×106 MethA
tumor cells in the left flank after an additional 2 years. Delayed tumor
growth 3 months after tumor cell transplantation is marked by ¥ (in two
mice) or F- (in one mouse).
Table 1 | Number of mice protected from MethA tumor growth after
immunization with irradiated mp53-transduced D2SC/1 cells.
Cellular vaccine Subcutaneous Intravenous
injection of injection of
transduced D2SC/1 transduced D2SC/1
D2SC/1-p53C132F/E168G 7b (n=12) 5 (n=12)
D2SC/1-p53M234I 8a (n=12) 7b (n=12)
D2SC/1-LacZ 0 (n=12) 0 (n=12)
aDelayed MethA tumor growth 3 months post MethA tumor cell inoculation in
two mice.
bDelayed MethA tumor growth 3 months post MethA tumor cell inoculation in
one mouse.
Immunization was performed as described in Figure 3. Data obtained 3 months
after first MethA tumor cell transplantation are summarized.
tumors were excised, explants were mechanically dissociated by
a 200µm mesh screen, and the resultant single cell suspensions
were examined by flow cytometry or immunoblotting to test
the possibility that a subset of tumor cells had downregulated
their mp53 expression (Figure 4). MethA tumor cells isolated
from mice vaccinated with D2SC/1–LacZ cells or the parental
in vitro cultured MethA cell line served as controls and displayed
high expression of p53. P53 levels from controls were compa-
rable to those found in samples from tumor biopsies isolated
from D2SC/1–mp53 vaccinated mice, when tumor growth was
not affected by the cellular vaccine. However, no p53 expression
was found in tumor cells isolated from D2SC/1–mp53 vaccinated
mice that were derived from tumors with delayed appearance.
This observation was independent of the mp53 allele used in the
vaccination protocol. Delayed tumor growth in DC immunized
mice is most likely the result of adaptive resistance, the down-
regulation of p53 expression resulting in the outgrowth of escape
variants.
FUSION OF D2SC/1 CELLS WITH MethA TUMOR CELLS
Native MethA tumor cells are most likely only weakly immuno-
genic, they express the MHC-class I alleles H-2K[d] and H-2D[d],
but not the MHC-class II allele I-A[d] and the co-stimulatory
molecules B7-1 and B7-2 (Figure 5A). MHC-class I associated
TA presentation is necessary for the interaction with cytotoxic T-
lymphocytes via the T-cell receptor and the induction of cellular
immunity. However, lack of co-stimulatory signals renders T-cells
tolerant and induces anergy or even cell death (42). We observed
the binding of alloreactive T-lymphocytes to MethA tumor cells
in vitro, but trypan blue exclusion assays revealed that the bound
T-cells were not vital, whereas, MethA tumor cells excluded the
dye (Figure 5B). Furthermore, naïve T-lymphocytes did not pro-
liferate in the presence of IL-2 or phorbol myristate acetate and
ionomycin when exposed to MethA cell culture supernatants (data
on file).
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FIGURE 4 | Outgrowth of p53 negative MethA tumor cells in mice that
were immunized by irradiated D2SC/1–mp53. MethA tumors were excised
from tumor bearing mice and single cell suspensions were assayed for p53
expression by flow cytometry (A) or immunoblotting (B). Parental, in vitro
cultured MethA cells and MethA tumor cells isolated from mice that were
treated with irradiated LacZ transduced D2SC/1 cells served as controls. The
immunization procedure and tumor appearance are indicated at the top of
each image. The β-actin antibody was used as a loading control.
D2SC/1 cells express high levels of B7-1, B7-2, MHC-class I,
and MHC-class II molecules on their cell surface (Figure 1).
These co-stimulatory molecules are responsible for the potency
of these cells as professional APCs and their capacity to stimulate
anti-tumor T-cells. Table 1 and Figure 3 show that TA expressing
D2SC/1 cells confer protective immunity in vivo, but that the anti-
tumor immune response can be impaired by the downregulation
of mp53, the applied TA (Figure 4).
The fusion of tumor cells with D2SC/1 cells can result in a
cellular vaccine that is potentially able to present the majority of
TAs characteristic for MethA cells and combine them with the DC
capabilities of processing, presentation, and immune stimulation.
The provision of vaccines presenting a wide range of tumor cell
epitopes can potentially enhance selective pressure and prevent
the evolution of tumor cell escape variants. For generation of the
fusion hybrids, we stably transfected D2SC/1 with a puromycin
and MethA tumor cells with a hygromycin B selection marker.
Resistant clones of both cell lines were isolated and fused through
exposure to polyethylene glycol. The fusion products were selected
through the simultaneous exposure of the cells to puromycin and
hygromycin B and 56 individual cell hybrid clones were isolated.
Twenty-four hybrid clones were further characterized. Flow cyto-
metric analyses indicated the expression of MHC complexes and
the co-stimulatory molecules B7-1 and B7-2 (Table 2, Figure 6).
Most of the analyzed clones expressed all of the surface proteins
tested, although the density of MHC I, MHC II, B7-1, and B7-2
varied in individual hybrid clones. Characterized clones were sub-
sequently used for the vaccination of mice and the animals were
challenged with MethA tumor cells.
VACCINATION OF MICE WITH D2SC/1-MethA CELL HYBRIDS
5× 106 D2SC/1-MethA cells derived from of a single hybrid clone
were injected subcutaneously in the right flank of Balb/c mice. One
week after the inoculation, small nodules of 2–3 mm in diameter
formed at the site of injection as hybrid clones were not irradi-
ated before their application and D2SC/1 or MethA tumor cells
form aggressive tumors when injected into mice. These nodules
progressively diminished within 2 weeks, indicating the induction
of a specific immune response (data on file). However, 5 out of
24 D2SC/1–MethA hybrid clones developed tumors (Table 2).
The aggressiveness of these five clones could not be correlated
with the expression profile of MHC complexes or the B7-1 and
B7-2 co-stimulatory molecules (Table 2; Figure 6).
Four weeks after the vaccination with D2SC/1–MethA cells, the
remaining 19 mice were challenged with 5× 106 parental MethA
tumor cells. The cells were injected subcutaneously in the opposite
left flank to monitor potential tumor growth. Alternatively, 5× 106
MethA tumor cells were injected intravenously into the tail veins
Frontiers in Oncology | Tumor Immunity October 2014 | Volume 4 | Article 270 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Humar et al. Prevention of adaptive tumor escape
A
B
MHC I (H-2K[d])
- FITC
MHC I (H-2D[d])
- FITC
MHC II (I-A[d])
- FITC
CD80 (B7-1)
- FITC
CD86 (B7-2)
- FITC
c
o
u
n
ts
c
o
u
n
ts
c
o
u
n
ts
c
o
u
n
ts
c
o
u
n
ts
FIGURE 5 | MethA tumor cells are resistant toT-cell activation in vitro.
(A) Flow cytometric analysis of MethA tumor cells stained with anti-H-2K[d]
(clone SF1-1.1), anti-H-2D[d] (clone 34-2-12), anti-I-A[d] (clone AMS-32.1),
anti-B7-1 (clone 16-10A1), and anti-B7-2 (clone GL-1) antibodies. Filled
histograms represent control staining without the primary antibody (isotype
control), open histograms the indicated surface marker. (B) T-cells isolated
from C57/BL6 mice and MethA tumor cells were co-cultured in proliferation
medium (DMEM, 10% FCS, 10 mM HEPES/pH7.4, 50µM
ß-mercaptoethanol, 0.4 ng/ml IL-2, 100 U/ml penicillin, and 100µg/ml
streptomycin) for 3 days and analyzed by a trypan blue exclusion assay. A
vital MethA tumor cell is shown that excludes the dye, whereas, bound
T-lymphocytes are intensively stained.
of the mice to determine the possible formation of lung metastasis
(27). Table 2 summarizes the results of these experiments. Fusion
of D2SC/1 cells with MethA tumor cells produced hybrid cells that
have largely lost their ability to form tumors. These fusion hybrids
assumed the role of a potent vaccine and quantitatively protected
mice, after only a single application of the cells, from growth of
MethA tumor cells. MethA tumor cells transiently formed small
nodules at the site of injection in treated mice; however, these nod-
ules regressed within 2 weeks when MethA cells were supplied to
D2SC/1–MethA vaccinated animals. We conclude that a specific
immune response deleted the MethA tumor cells.
Mice, immunized with individual hybrid variants were also pro-
tected from lung metastasis formed by MethA cells upon tail vein
injection (Table 2). Control mice, not treated with the cellular
vaccine, exhibited unrestricted MethA tumor growth and devel-
oped metastases in the lung (data on file). Vaccinated, tumor
resistant mice were exposed to a second challenge with MethA cells
24 months later. All animals rejected the transplanted tumor cells.
This indicates a long-lasting immunological memory (Table 2).
IMMUNE EFFECTOR MECHANISMS
The induction of systemic anti-tumor immunity and the establish-
ment of immunological memory are the characteristic features of
adaptive immune responses. We observed that mice, transplanted
with the cellular D2SC/1 vaccines at distinct sites, responded to
the second challenge with MethA tumor cells 2 years after the
initial immunization and exhibited resistance against tumor and
metastasis formation (Table 2). Therefore, we analyzed the mice
vaccinated with D2SC/1–mp53 cells or D2SC/1–MethA cells for
the presence of major effectors of the adaptive immune response,
characteristic for immunological memory.
Dendritic cells stimulate growth and differentiation of antigen-
specific B-lymphocytes (43). To investigate whether D2SC/1 inoc-
ulated mice express TA specific antibodies, we obtained serum
from Balb/c mice vaccinated with D2SC/1–LacZ, D2SC/1–mp53,
and D2SC/1–MethA. Blood samples were taken from the lateral
tail vein before and after vaccination. The sera were tested for
the presence of MethA specific antibodies by exposure to mem-
branes onto which MethA tumor cell lysates or purified mp53 were
immobilized (Figure 7). Our results show that only antibodies
present in sera from mice vaccinated with D2SC/1–MethA, which
had rejected the MethA tumor cell challenge, recognized multiple
MethA tumor cell proteins. These antibodies were not found in
pre-immune sera or in sera from mice vaccinated with D2SC/1–
mp53. Also, sera from control mice inoculated with MethA tumor
cells without D2SC/1 vaccination, from mice vaccinated with
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Table 2 | Characterization of D2SC/1–MethA fusion hybrid clones and their potential as a cellular vaccine.
Fusion hybrid Expression of H-2 Rejection of fusion hybrid in Protective immunity in Balb/c mice against Immunologic
ID number Balb/c or Balb/c nude solid tumor growth or metastasis of MethA memory in Balb/c
K[d] D[d] A[d] B7-1 B7-2
MeDC1 ++ +++ ++ +++ ++ Yes No Yes Yes Yes
MeDC2 +++ +++ − + − Yes No Yes Yes Yes
MeDC3 +++ +++ − − − Yes No Yes Yes Yes
MeDC4 ++ +++ − + − Yes No Yes Yes Yes
MeDC5 ++ ++ ++ ++ + Yes No Yes Yes Yes
MeDC6 ++ ++ + + + Yes No No No n.d.
MeDC7 ++ ++ + ++ + Yes No Yes Yes Yes
MeDC8 ++ ++ − + − Yes No Yes Yes Yes
MeDC9 ++ ++ ++ ++ + Yes No Yes Yes Yes
MeDC10 +++ +++ − − − Yes No Yes Yes Yes
MeDC11 +++ +++ − − − No No n.d. n.d. n.d.
MeDC12 ++ ++ ++ ++ + No No n.d. n.d. n.d.
MeDC13 +++ +++ ++ ++ + Yes No Yes Yes Yes
MeDC14 + ++ + ++ + No No n.d. n.d. n.d.
MeDC15 ++ ++ − − − Yes No Yes Yes Yes
MeDC16 ++ ++ + + + No No n.d. n.d. n.d.
MeDC17 ++ ++ + + − Yes No Yes Yes Yes
MeDC18 ++ +++ + + − Yes No Yes Yes Yes
MeDC19 +++ +++ ++ ++ ++ Yes No Yes Yes Yes
MeDC20 +++ +++ − − − Yes No Yes Yes Yes
MeDC21 ++ + + ++ + No No n.d. n.d. n.d.
MeDC22 ++ ++ + ++ ++ Yes No Yes Yes Yes
MeDC23 ++ ++ ++ ++ + Yes No Yes Yes Yes
MeDC24 +++ +++ − + − Yes No Yes Yes Yes
(−) increase in expression by <25%, (+) by 25–50%, (++) by 50–80%, or (+++) by more than 80%; n.d., not determined.
Cell surface marker expression was analyzed by flow cytometry. Additionally, rejection of individual transplanted fusion hybrid clones or MethA tumor cells is shown.
Immunologic memory was proven by a second rejection of MethA tumor cells, transplanted to mice 2 years after the first MethA tumor cell inoculation.
D2SC/1–lacZ or from mice vaccinated with D2SC/1–MethA that
were not protected against the MethA tumor cell challenge, did
not contain antibodies of this specificity. These results show
that MethA reactive antibodies are specifically induced in mice,
upon vaccination with D2SC/1–MethA, which are able to sup-
press tumor cell growth and indicate that these antibodies might
be involved in this process.
We evaluated the relative contribution of B-lymphocytes to
the anti-tumor response in our mouse model. Athymic nude
mice were vaccinated by subcutaneous injection of non-irradiated
D2SC/1–MethA hybrid cells. The athymic nude mice are char-
acterized by a defective T-cell response and immune responses
in these animals are independent of mature T-lymphocytes. We
observed aggressive tumor growth upon transfer of D2SC/1–
MethA hybrid cells into the athymic nude mice. These tumors were
not eliminated by the immune system (Table 2). We also observed
that the growth kinetics of individual fusion clones varied substan-
tially (data on file). This indicates that individual clones possess
different potentials for tumorigenicity, possibly reflected in dis-
tinguishable gene expression patterns (Table 2; Figure 6). We also
conclude that D2SC/1–MethA hybrid cells retain their tumori-
genicity in the absence of T-lymphocytes. It is conceivable that
co-stimulatory CD4+ T-cells may assist B-lymphocyte activation
and the induction of humoral immunity.
MethA TUMOR REJECTION IS MEDIATED BY T-LYMPHOCYTES
Despite the potential involvement of B-cells and MethA specific
antibodies, we hypothesize that differentiated cytotoxic CD8+
T-lymphocytes are the critical mediators of the induced anti-
tumor immunity. They are most likely activated by MHC-class
I TA peptide complexes on the surface of the fusion hybrids
and are then able to lyse the tumor cells and the observed
growth of the D2SC/1–MethA hybrid clones in athymic nude
mice supports this notion. To corroborate this observation, we
directly investigated whether vaccination with D2SC/1–MethA
fusion hybrids induces a specific T-cell response. Balb/c mice
resistant against the challenge with MethA tumor cells were used
and T-lymphocytes from their spleens were isolated. T-cells from
non-immunized mice, challenged with MethA tumor cells served
as controls. The T-cells were co-cultured with D2SC/1–MethA
cells and their proliferative response was measured. Our results
show that T-cells from protected, vaccinated animals can be acti-
vated in the presence of fusion hybrids (see Figure 8). T-cells
from unprotected control animals were not growth stimulated.
Frontiers in Oncology | Tumor Immunity October 2014 | Volume 4 | Article 270 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Humar et al. Prevention of adaptive tumor escape
A
B
C
D
E
F
c
o
u
n
ts
MHC I (H-2K[d])
- FITC
MHC I (H-2D[d])
- FITC
MHC II (I-A[d])
- FITC
CD80 (B7-1)
- FITC
CD86 (B7-2)
- FITC
MEDC1 MEDC1 MEDC1 MEDC1 MEDC1
MEDC18 MEDC18 MEDC18 MEDC18 MEDC18
MEDC20 MEDC20 MEDC20 MEDC20 MEDC20
MEDC12 MEDC12 MEDC12 MEDC12 MEDC12
MEDC6 MEDC6 MEDC6 MEDC6 MEDC6
MEDC11 MEDC11 MEDC11 MEDC11 MEDC11
FIGURE 6 | Continued
www.frontiersin.org October 2014 | Volume 4 | Article 270 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Humar et al. Prevention of adaptive tumor escape
FIGURE 6 | Continued
Characterization of individual D2SC/1-MethA fusion hybrids by flow
cytometry. Expression of MHC complexes and B7 co-stimulatory molecules
of clone MeDC1 (A), MeDC18 (B), MeDC20 (C), MeDC12 (D), MeDC6
(E), and MeDC11 (F) were analyzed with anti-H-2K[d] (clone SF1-1.1),
anti-H-2D[d] (clone 34-2-12), anti-I-A[d] (clone AMS-32.1), anti-B7-1 (clone
16-10A1), and anti-B7-2 (clone GL-1) antibodies. Filled histograms represent
control staining without the primary antibody (isotype control), open
histograms the indicated surface marker. Clones that mediate MethA tumor
rejection are MeDC1, MeDC18, and MeDC20. Clones that remain
tumorigenic are MeDC11 and MeDC12. Clone MeDC6 does not mediate
protective anti-tumor immunity, although it has lost tumorigenicity.
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FIGURE 7 | Polyclonal B-cell activation by D2SC/1–MethA fusion hybrids.
Balb/c mice were vaccinated with 5×106 transduced and irradiated D2SC/1
cells or non-irradiated fusion hybrid clones and inoculated s.c. with 5×106
MethA tumor cells. Blood sera were isolated 10 days post tumor cell
transplantation and analyzed by immunoblotting at a dilution of 1:400 using
blotted MethA tumor cell lysates (A) or purified mp53 (B). Donor mice are
indicated by numbers and vaccine at the top of the blots, MethA tumor cell
inoculation is displayed at the bottom of the blots. Pre-immune serum (A1–3),
sera from mice 10 days post MethA tumor cell transplantation (A4–5), sera
from fusion hybrid vaccinated mice that do not mediate MethA rejection:
MeDC16 (A6), MeDC21 (A7), MeDC6 (A8), MeDC11 (A9), MeDC14 (A10), and
MeDC12 (A11), sera from fusion hybrid vaccinated mice that mediate MethA
rejection: MeDC7 (A12, B2, B28), MeDC24 (A13, B3, B29), MeDC22 (A14,
B4, B30), MeDC13 (A15, B5, B31), MeDC4 (A16, B6, B32), MeDC2 (A17, B7,
B33), MeDC8 (A18, B8, B34), MeDC3 (A19, B9, B35), MeDC9 (A20, B10,
B36), MeDC15 (A21, B11, B37), MeDC10 (A22, B12, B38), MeDC23 (A23,
B13, B39), MeDC5 (A24, B15, B41), MeDC17 (A25, B16, B42), MeDC1 (A26,
B17, B43), MeDC19 (A27, B18, B44), MeDC20 (A28, B19, B45), and MeDC18
(A29, B20, B46), sera from D2SC/1–LacZ vaccinated mice after MethA
transplantation (A30–32), sera from D2SC/1–p53M234I vaccinated mice after
MethA transplantation (A33–36, B21–23, B47–49), and sera from
D2SC/1–p53C132F/E168G vaccinated mice after MethA transplantation
(A37–40, B24–26, B50–52), positive control using 1µg/ml anti-p53 PAb 421
antibody (B1, B14, B27, B40).
D2SC/1 cells, used as target cells, were not able to elicit the pro-
liferative effect, i.e., the T-cell recognized the MethA tumor cells
(data on file).
To further define the effectors responsible for the anti-tumor
cell immunity, CD4+ or CD8+ T-lymphocytes were depleted from
Balb/c mice by injection of either anti-CD4 or anti-CD8 specific
antibodies. Such animals were then vaccinated with D2SC/1–
MethA fusion hybrids and challenged with MethA tumor cells.
Our results show (Figures 9A–C) that the protection from MethA
induced tumor growth requires both CD4+ and CD8+ T-cells. The
depletion of CD4+ or CD8+ T-lymphocytes abrogated the pro-
tective effect of the vaccination. We conclude that a CD4+-assisted
B-lymphocyte response and a robust activation of tumor-specific
cytotoxic T-cells might cooperate in the anti-tumor cell immunity,
induced by the D2SC/1–MethA cells.
DISCUSSION
Cellular immune therapy of cancer is well on its way into clinical
practice. Vaccine-induced expansion of antigen-specific effector
T-cells and clinical responses have been observed in the treatment
of vulvar intraepithelial neoplasia and treatment of metastatic
melanoma patients with ipilimumab improved their survival (44,
45). Clinical responses, however, were not always satisfactory. Ben-
efits were only observed in a fraction of patients and TA specific
immune responses often did not correlate with tumor rejection,
stabilization of disease, or overall survival (7). The procedures of
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immune therapy still have to be optimized. Counteracting tumor
evasion mechanisms, the identification and utilization of new TAs
and the design of innovative vaccination protocols could pave
the way.
Our study contributes two potentially valuable aspects: (1)
immortalized D2SC/1 DCs can efficiently be used to present
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FIGURE 8 | Fusion hybrid dependentT-cell activation. Fusion hybrid
specific T-lymphocytes were detected by a [3H]thymidine incorporation
assay. Balb/c mice were vaccinated with 5×106 non-irradiated fusion
hybrids, inoculated with 5×106 MethA tumor cells and dissected to isolate
spleen derived T-lymphocytes. 1.28×106 T-cells were titrated by a fourfold
dilution before proliferation was induced by co-culture with 2×104 irradiated
(200 gray) hybrid fusion clones for 72 h. One microcurie [3H]thymidine was
added for the last 15 h of the experiment. Clones used for vaccination and
in vitro target cells are MeDC1 ( ), MeDC18 ( ), and MeDC20 (). In
control experiments, effector T-cells from non-vaccinated, 5×106 MethA
tumor cell inoculated mice were similarly exposed to 2×104 irradiated
MeDC1 (♦), MeDC18 (∆), or MeDC20 () cells in vitro. Values represent
the ±standard error of the means (n=3) after subtracting thymidine
incorporation in the absence of stimulator cells. Statistical differences using
MeDC1 (**p<0.01; ***p<0.001), MeDC18 (###p<0.001), or MeDC20
(¥p<0.05; ¥¥¥p<0.001) target cells were determined by performing
one-way ANOVA followed by the Bonferroni’s post hoc test.
immunogenic epitopes of mutated p53 variants after retroviral
transduction and induce a robust rejection of MethA fibrosar-
coma cells. We also observed that the MethA tumor cells can evolve
under the pressure exerted by immune cells and downregulate the
expression of mutated p53 alleles. This results in the outgrowth
of MethA escape variants. (2) A more comprehensive and sus-
tained immune protection was achieved when D2SC/1 cells were
fused with MethA and the hybrid cells were employed as vac-
cines. The hybrid cells combine the expression of a large variety of
MethA specific genes and the processing and presentation capa-
bilities of DCs. These cells are able to induce a protective immune
response, which cannot easily be subverted by escape variants of
the tumor cells.
The p53 tumor suppressor seems an attractive candidate as a
functional TA (46, 47). p53 is found to be mutated in about 50% of
all human tumors and the mutated protein accumulates in the can-
cer cells. p53 mediated signaling pathways are abnormal in nearly
all human malignancies. Although the mutations in the p53 gene
can occur at different positions, hotspots have been identified and
immune responses to mutated or overexpressed p53 have been
found. p53-specific epitopes can be presented by MHC-class I and
MHC-class II molecules and p53-specific CD8+ CTLs or CD4+
T-helper cells have been detected as well as p53-specific circulating
antibodies (24–26). p53 has shown its value as a target in immune
therapy in animal models and in patients (27, 30).
The selection of suitable TAs in immune therapy has to be com-
plemented by proper ways of administration to achieve sustained
anti-tumor immunity. DCs seem the route of choice (14, 18). They
are able to degrade and present immunogenic peptides in the con-
text of MHC molecules. Various procedures have been developed
to supply DCs with TAs. The exposure of DCs to exogenous anti-
gens is mainly associated with MHC-class II presentation and the
induction of helper T-lymphocyte dependent humoral immunity.
Antigen loading by transfer of genes into DCs and intracellular
transgene expression targets processed peptides to MHC-class I
presentation and CTL induction.
Transfer of mp53-transduced DCs triggered systemic immu-
nity and immunological memory against MethA tumors, most
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FIGURE 9 | Depletion ofT-lymphocytes results in loss of fusion hybrid
induced anti-tumor immunity. MethA tumor growth is shown in
CD4-depleted (∆) or CD8-depleted () Balb/c mice. T-cell depleted mice
were vaccinated with 5×106 MeDC1 (A), MeDC18 (B), or MeDC20
(C) 28 days before inoculation with 5×106 MethA tumor cells. , MethA
tumor growth in non-vaccinated, non-depleted CD4+/CD8+ Balb/c mice. *,
MethA tumor growth in fusion hybrid vaccinated, non-depleted
CD4+/CD8+ Balb/c mice.
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likely through the induction of specific immune effector cells.
Immunization was most efficient with p53M234I transduced DCs.
The mutation in codon 234 of mp53, resulting in a methionine to
isoleucine substitution, is associated with the formation of a new
anchor position within the MHC-class I pocket and thus might
result in the presentation of a new tumor-specific antigen for CTL
(48). Correspondingly, isoleucine at position 3 in K[d]-restricted
non-amers is a far more frequent residue then methionine. How-
ever, p53C132F/E168G transduced DCs also induced anti-tumor
immunity, although these mutated sites have not been predicted
to be relevant for MHC-class I presentation. The relevant epitope,
which triggers MethA tumor rejection in animals vaccinated with
D2SC/1–p53C132F/E168G has still to be identified.
Cancer cells, under the onslaught of chemotherapeutic agents
or immune cells, evolve and acquire resistant phenotypes. Inher-
ent, acquired and adaptive resistance mechanisms have been iden-
tified. We found that MethA cells can escape the mp53 specific
immune response by downregulation of p53 expression. Immune
tolerance and resumption of tumor cell growth after the induction
of a TA specific immune response have been observed before (49).
It will be interesting to analyze the MethA tumors with downregu-
lated p53 expression for alterations in transformation parameters
and drug responsiveness.
The emergence of tumor escape variants can possibly be
avoided by the use of vaccines, which present multiple TAs. We
used fusions of tumor cells with DCs to obtain fusion hybrids.
These cells possibly express all TAs and combine it with the
immune stimulatory capacities of APCs (17, 42). Immunity might
be enhanced because different TAs may induce different immune
effector mechanisms (50, 51). Upon establishment of a vaccina-
tion protocol, the generation of tumor/DC-fusion hybrids may
thus result in a simple form of personalized anti-cancer treatment.
Fusion hybrids induced a marked humoral immune response
in vivo, a tumor-specific proliferative T-cell response in vitro, and
prevented the emergence of tumor escape variants. Obviously,
the tumor/DC-fusion hybrids are more effective therapeutic tools
than single TA encoding vaccines. The broad and robust induc-
tion of specific immune effector mechanisms might be explained
by the presentation of an increased number of TAs, some of them
with stronger immune stimulatory capacity than mp53. Indeed,
we observed the clonal expansion of multiple antigen-specific
B-cells.
Immune responses induced by fusion hybrids have mainly
been associated with the induction of tumor-specific CTLs (51).
We additionally observed a marked humoral immune response,
which could contribute to efficient anti-tumor responses. Strong
humoral responses usually reflect large tumor burden and the
failure of anti-tumor immune responses. However, IgG antibodies
could also lead to opsonization, Fc receptor dependent internaliza-
tion, processing, and antigen presentation in DCs and thus might
promote tumor rejection. MethA specific polyclonal B-cell activa-
tion was only found in mice resistant to tumor growth upon fusion
hybrid vaccination. However, athymic nude mice were not pro-
tected. If this is due to the lack of helper T-lymphocyte dependent
B-cell stimulation remains to be investigated.
Induction of long-lasting protective immunity is the primary
aim in vaccination against cancer. The cytotoxic immune response
is the pivotal element for persistent elimination of tumors (19). We
demonstrated a strong anti-tumor response mediated by CD3+ T-
lymphocytes from fusion hybrid vaccinated mice. Our depletion
studies confirmed that both cytotoxic and helper T-lymphocytes
were essential for tumor rejection. Most known TAs are restricted
to MHC-class I presentation, but MHC-class II restricted TA epi-
topes have also been identified. TAs might enable both CD4+ and
CD8+ T-cell activation.
The therapeutic efficiency of DCs fused with autologous
tumors has been associated with increased TA presentation and
efficient co-stimulation of immune effector cells (17, 42). In our
experiments, various DC-fusion hybrid clones were character-
ized by different expression profiles of antigen presenting and
co-stimulatory molecules that did not necessarily reflect vacci-
nation efficacy. Obviously, in some clones expression of MHC
complexes and B7 co-stimulatory molecules was not sufficient
to induce their rejection by the immune competent host. DCs
are potent activators of regulatory CD4+ CD25+ Foxp3+ reg-
ulatory T-cells that might downregulate an efficient anti-tumor
response (52, 53). Indeed, D2SC/1 cells are able to modulate reg-
ulatory T-cell activity under certain conditions (54). Additionally,
we observed that MethA tumor cells are FasL+ and T-cells, cul-
tured in the presence of MethA tumor cells or MethA conditioned
medium, show decreased viability or reduced proliferative capac-
ity, which might contribute to the limited vaccination potential of
some fusion hybrid clones (Matjaz Humar, unpublished obser-
vation). On the other hand, lack of MHC II, B7-1, and B7-2
expression did not necessarily lead to tumor escape, indicating that
other yet unidentified immune stimulatory mechanisms partici-
pate in tumor cell rejection. These additional anti-tumor response
mechanisms and the probability that some hybrid clones may
favor tumor escape by activating regulatory T-cells or by express-
ing pro-apoptotic mediators need to be elucidated in further
experiments.
Vaccination against single TAs may induce an initial ther-
apeutic benefit, but eventually could yield variant tumor cells
evading the effector immune cells. Clinical trials based on the
induction of immune responses against a specific TA did not nec-
essarily prolong patient survival (55, 56). Based on our results
it would be worthwhile to investigate whether tumor recurrence
in those patients correlated with immune escape due to antigen
downregulation.
In conclusion, multi-antigen tumor vaccines have greater
therapeutic potential then DCs that present only one specific
tumor-antigen. Tumors often show heterologous protein expres-
sion and selective pressure to variants with specifically reduced
tumor-antigen levels will be only maintained by multi-antigen
directed tumor vaccines. In addition, multi-antigen tumor vac-
cines provide enhanced immunity because different TAs may
induce different immune effector mechanisms, resulting in a broad
immune response, and synergistic cross talk of diverse immune
effector mechanisms. Moreover, the generation of DC/tumor
fusion hybrids avoids the complex identification and charac-
terization of individual immune-stimulating tumor-antigens.
Thus, the administration of DC/tumor fusion hybrids may pro-
vide a simple and effective form of personalized anti-cancer
treatment.
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